Methods for treating and reducing traumatic brain injury-associated impairments using SGP130

Abstract

The present disclosure relates to methods and compositions for treating traumatic brain injury (TBI) and TBI-associated impairments and improving outcome in subjects that have sustained traumatic brain injury comprising administering to the subject a sgp130 or an agent that promotes the binding of sgp130 and sIL-6R and/or reduces sIL-6R mediated trans-signaling. The present disclosure also relates to methods and kits for identifying a subject that is at risk of developing a TBI-associated impairment (e.g., headache, depression, cognitive deficits, and seizure) or monitoring the responsiveness to a treatment regimen for a TBI-associated impairment in the subject, using biomarkers (e.g., white blood cells indices (e.g., Neutrophil-Lymphocyte Ratio (NLR), absolute lymphocyte counts), sIL-6R, sgp130, IL-6, sgp130:sIL-6R ratio, sIL-2Ra, IL-2, sIL-2Ra:IL-2 ratio, TNFα, TNFRI, and TNFRI:TNFα ratio).

Dependencies are inferred from the claim text.